Physician profile
Ming Xu
NPI 1548271018
$505,223.14
in general payments reported to CMS, 2019-2025
26 companies · $117K in 2025
The $117K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $45K · 2021: $52K · 2022: $77K · 2023: $104K · 2024: $98K · 2025: $117K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $228K · Consulting Fee: $39K · Honoraria: $24K · Travel and Lodging: $17K · Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $227,573.00 |
| Consulting Fee | $39,195.00 |
| Honoraria | $24,200.00 |
| Travel and Lodging | $16,972.51 |
| Food and Beverage | $10,501.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $184,275.81 | 2021-2025 | Vraylar |
| Allergan, INC. | $59,327.25 | 2019-2021 | |
| Axsome Therapeutics, INC. | $55,241.03 | 2022-2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $48,616.70 | 2022-2025 | Qelbree, Qelbree |
| Alkermes, INC. | $34,529.22 | 2022-2025 | Lybalvi, Aristada |
| E.R. Squibb & Sons, L.L.C. | $32,243.78 | 2024-2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $31,587.39 | 2020-2024 | Caplyta |
| Vanda Pharmaceuticals INC. | $24,124.26 | 2022-2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $17,631.35 | 2022-2025 | Uzedy, Austedo Xr |
| Corium, LLC | $8,621.44 | 2023-2024 | Azstarys, Azstarys |
| Idorsia Pharmaceuticals US INC | $7,466.02 | 2023 | Quviviq |
| Sunovion Pharmaceuticals INC. | $322.25 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $299.82 | 2019-2023 | Abilify Maintena |
| Janssen Pharmaceuticals, INC | $192.03 | 2020-2023 | Invega Trinza, Invega Sustenna, Spravato |
| Biogen, INC. | $179.40 | 2020-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Microvention, INC. | $117.07 | 2021 | |
| Eisai INC. | $104.40 | 2020-2021 | |
| Lundbeck LLC | $94.56 | 2022-2023 | Abilify Maintena |
| Merck Sharp & Dohme LLC | $52.73 | 2021-2023 | Belsomra |
| Boston Scientific Corporation | $51.26 | 2023 | Spaceoar System |
| Almatica Pharma LLC | $40.28 | 2021-2022 | |
| Bausch Health US, LLC | $38.98 | 2022 | |
| Indivior INC. | $21.19 | 2022 | |
| Neurocrine Biosciences, INC. | $16.81 | 2022 | |
| Ironshore Pharmaceuticals INC. | $15.81 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ming Xu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.